VVOS Vivos Therapeutics Inc
Price (delayed)
$2.52
Market cap
$14.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.22
Enterprise value
$10.09M
Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that
Highlights
VVOS's EPS has soared by 80% YoY and by 61% from the previous quarter
Vivos Therapeutics's debt has decreased by 24% YoY and by 8% from the previous quarter
The company's gross margin fell by 2.9% QoQ
Key stats
What are the main financial stats of VVOS
Market
Valuations
Earnings
Shares outstanding
5.89M
Market cap
$14.84M
Enterprise value
$10.09M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.67
Revenue
$15.03M
Gross profit
$9.02M
Operating income
-$11.17M
Net income
-$11.14M
EBIT
-$11.14M
EBITDA
-$10.56M
Free cash flow
-$13.26M
Per share
Balance sheet
Liquidity
EPS
-$2.22
EPS diluted
-$2.22
Free cash flow per share
-$2.64
Book value per share
$1.64
Revenue per share
$2.99
TBVPS
$2.4
Total assets
$15.28M
Total liabilities
$7.33M
Debt
$1.51M
Equity
$7.95M
Working capital
$2.5M
Debt to equity
0.19
Current ratio
1.5
Quick ratio
1.34
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
-70.2%
Gross margin
60%
Net margin
-74.1%
Operating margin
-74.3%
Return on assets
-76.4%
Return on equity
-197.6%
Return on invested capital
-848.8%
Return on capital employed
-108.1%
Return on sales
-74.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VVOS stock price
How has the Vivos Therapeutics stock price performed over time
Intraday
9.57%
1 week
21.15%
1 month
-30%
1 year
-4.91%
YTD
-41.26%
QTD
-11.58%
Financial performance
How have Vivos Therapeutics's revenue and profit performed over time
Revenue
$15.03M
Gross profit
$9.02M
Operating income
-$11.17M
Net income
-$11.14M
Gross margin
60%
Net margin
-74.1%
The company's operating margin rose by 41% YoY and by 13% QoQ
Vivos Therapeutics's operating income has increased by 35% YoY and by 11% from the previous quarter
Vivos Therapeutics's net margin has increased by 25% YoY and by 14% from the previous quarter
The net income has grown by 18% YoY and by 11% from the previous quarter
Growth
What is Vivos Therapeutics's growth rate over time
Valuation
What is Vivos Therapeutics stock price valuation
P/E
N/A
P/B
1.53
P/S
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.67
VVOS's EPS has soared by 80% YoY and by 61% from the previous quarter
The price to book (P/B) is 89% lower than the 5-year quarterly average of 13.4 and 78% lower than the last 4 quarters average of 6.9
The equity has increased by 3.8% since the previous quarter
VVOS's P/S is 68% below its 5-year quarterly average of 2.6 and 16% below its last 4 quarters average of 1.0
Vivos Therapeutics's revenue has increased by 9% YoY and by 3.1% from the previous quarter
Efficiency
How efficient is Vivos Therapeutics business performance
The company's return on equity has surged by 65% YoY and by 41% QoQ
The return on invested capital has surged by 55% year-on-year and by 42% since the previous quarter
The company's return on assets rose by 27% YoY and by 18% QoQ
VVOS's ROS is up by 25% YoY and by 14% from the previous quarter
Dividends
What is VVOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VVOS.
Financial health
How did Vivos Therapeutics financials performed over time
VVOS's total assets is 109% higher than its total liabilities
VVOS's total assets is up by 42% YoY
The company's total liabilities fell by 29% YoY and by 4.6% QoQ
Vivos Therapeutics's debt is 81% less than its equity
VVOS's debt to equity has dropped by 96% year-on-year and by 10% since the previous quarter
Vivos Therapeutics's debt has decreased by 24% YoY and by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.